UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(RULE
14D-100)
Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
(Amendment No. 2)
ARIAD
Pharmaceuticals, Inc.
(Name of Subject Company)
KIKU MERGER CO., INC.
(Offeror)
TAKEDA
PHARMACEUTICAL COMPANY LIMITED
(Parent of Offeror)
(Names of Filing Persons)
Common stock, par value $0.001 per share
(Title of Class of Securities)
04033A100
(CUSIP Number
of Class of Securities)
James Kehoe
Takeda Pharmaceutical Company Limited
12-10,
Nihonbashi
2-chome,
Chuo-ku,
Tokyo
103-8668
Tel: +81 3 3278-2111
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)
With a copy to:
Paul J. Shim
Kimberly R.
Spoerri
Cleary Gottlieb Steen & Hamilton LLP
One Liberty Plaza
New
York, New York 10006
(212)
225-2000
CALCULATION OF FILING FEE
|
|
|
Transaction Valuation*
|
|
Amount of Filing Fee**
|
$4,898,591,936
|
|
$567,746.81
|
|
*
|
Calculated solely for purposes of determining the filing fee. The calculation of the transaction value is determined by adding the sum of (i) 194,580,850 shares of common stock, par value $0.001 per share, of ARIAD
Pharmaceuticals, Inc. multiplied by the offer price of $24.00 per share, (ii) 9,236,071 shares subject to issuance pursuant to granted and outstanding stock options multiplied by $15.11 (which is calculated by subtracting $8.89, the weighted average
price of all outstanding stock options, from the offer price of $24.00 per share), (iii) 1,901,731 shares subject to issuance pursuant to granted and outstanding restricted stock units multiplied by the offer price of $24.00 per share, (iv)
1,788,540 shares subject to issuance pursuant to granted and outstanding performance stock units at the greater of (A) the target level of performance for each such performance stock unit and (B) the estimated actual level of performance
determined as of January 13, 2017, multiplied by the offer price of $24.00 per share, and (v) 22,000 shares estimated to be subject to outstanding purchase rights under ARIADs 2007 Employee Stock Purchase Plan multiplied by the offer
price of $24.00 per share. The calculation of the filing fee is based on information provided by ARIAD as of January 13, 2017.
|
**
|
The filing fee was calculated in accordance with Rule
0-11
under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for Fiscal Year 2017, issued
August 31, 2016, by multiplying the transaction valuation by 0.0001159.
|
☒
|
Check box if any part of the fee is offset as provided by
Rule 0-11(a)(2)
and identify the filing with which the offsetting fee was previously paid. Identify the previous
filing by registration statement number, or the form or schedule and the date of its filing.
|
|
|
|
Amount Previously Paid: $567,746.81
Form or
Registration No: Schedule TO
|
|
Filing Party: Kiku Merger Co., Inc. and Takeda Pharmaceutical Company Limited
Date Filed: January 19, 2017
|
☐
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions to which the statement relates:
|
☒
|
third-party tender offer subject to
Rule 14d-1.
|
|
☐
|
issuer tender offer subject to
Rule 13e-4.
|
|
☐
|
going-private transaction subject to
Rule 13e-3.
|
|
☐
|
amendment to Schedule 13D under
Rule 13d-2.
|
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
This Amendment No. 2 (this Amendment) amends and supplements the Tender Offer Statement on
Schedule TO filed by Kiku Merger Co., Inc., a Delaware corporation (Purchaser) and a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (Takeda), with
the Securities and Exchange Commission on January 19, 2017 (together with any subsequent amendments and supplements thereto, including this Amendment, the Schedule TO). The Schedule TO relates to the tender offer by Purchaser for
all of the outstanding shares of common stock, par value $0.001 per share (Shares), of ARIAD Pharmaceuticals, Inc., a Delaware corporation (ARIAD), at a price of $24.00 per Share in cash, net of applicable withholding taxes
and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 19, 2017 (the Offer to Purchase), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of
transmittal (the Letter of Transmittal, a copy of which is attached as Exhibit (a)(1)(B), and which, together with the Offer to Purchase and other related materials, as each may be amended or supplemented from time to time, collectively
constitute the Offer).
All the information set forth in the Offer to Purchase, including Schedule I thereto, is incorporated by reference
herein in response to Items 1 through 9 and Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Amendment.
Capitalized terms used but not defined in this Amendment shall have the meanings assigned to such terms in the Schedule TO.
Items 1 through 9 and Item 11.
The Offer to Purchase and
Items 1 through 9 and Item 11 of the Schedule TO, to the extent such Items incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented as set forth below:
|
(1)
|
The fourth paragraph of the Offer to Purchase is amended and supplemented by adding the following sentences at the end of the paragraph:
|
The Regulatory Condition has been satisfied by the early termination of the waiting period effective January 30, 2017. The Offer
continues to be subject to the remaining conditions set forth in this Offer to Purchase.
|
(2)
|
The fourth paragraph of the Introduction to the Offer to Purchase is amended and supplemented by adding the following sentences at the end of the paragraph:
|
The Regulatory Condition has been satisfied by the early termination of the waiting period effective January 30, 2017. The Offer
continues to be subject to the remaining conditions set forth in this Offer to Purchase.
|
(3)
|
Section 15 Conditions of the Offer of the Offer to Purchase is amended and supplemented by adding the following sentences after the last paragraph of Section 15:
|
The Regulatory Condition has been satisfied by the early termination of the waiting period effective January 30, 2017. The Offer
continues to be subject to the remaining conditions set forth in this Offer to Purchase.
|
(4)
|
The second paragraph of the subsection titled Compliance with the HSR Act in Section 16 Certain Legal Matters; Regulatory Approvals of the Offer to Purchase, as such paragraph was amended
by Amendment No. 1 to the Schedule TO filed with the SEC on January 24, 2017, is amended and supplemented by adding the following sentences to the end of the paragraph:
|
On January 30, 2017, the FTC granted early termination of the required waiting period under the HSR Act with respect to the Offer.
Accordingly, the Regulatory Condition has been satisfied. The Offer continues to be subject to the remaining conditions set forth in this Offer to Purchase.
|
(5)
|
The subsection titled Litigation in Section 16 Certain Legal Matters; Regulatory Approvals of the Offer to Purchase is amended and supplemented by replacing the current disclosure in
its entirety to read as follows:
|
Three purported class action complaints related to the Merger have been filed in the
United States District Court for the District of Massachusetts on behalf of putative classes of ARIADs public shareholders. The three complaints, all of which were filed on January 28, 2017, are captioned:
Ventrice
v.
Ariad
Pharmaceuticals, Inc., et al.
, Case No. 17 Civ. 10151;
Pirouz
v.
Ariad Pharmaceuticals, Inc., et al.
, No. 17 Civ. 10152; and
Baumann
v.
Ariad Pharmaceuticals, Inc., et al.
, Case No. 17 Civ. 10153. All
three complaints name as defendants ARIAD and its directors, and two of the complaints (
Bauman
and
Ventrice
) also name Takeda and Purchaser as defendants. The complaints generally allege that ARIAD and its directors violated federal
securities laws by failing to disclose material information in the Companys January 19, 2017 Schedule
14D-9
Solicitation/Recommendation Statement. The
Bauman
and
Ventrice
complaints
also allege that the omissions constitute violations of federal securities laws by Takeda and Purchaser. The complaints seek, among other things, injunctive relief preventing the consummation of the Merger, damages, and an award of plaintiffs
expenses and attorneys fees. Defendants believe that the claims respectively asserted against them are without merit.
SIGNATURES
After due inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true,
complete and correct.
|
|
|
TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|
|
By:
|
|
/s/ Christophe Weber
|
Name:
|
|
Christophe Weber
|
Title:
|
|
President and Chief Executive Officer
|
|
KIKU MERGER CO., INC.
|
|
|
By:
|
|
/s/ Christophe Bianchi
|
Name:
|
|
Christophe Bianchi
|
Title:
|
|
President
|
Dated: January 30, 2017
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
(a)(1)(A)
|
|
Offer to Purchase, dated January 19, 2017.*
|
|
|
(a)(1)(B)
|
|
Letter of Transmittal.*
|
|
|
(a)(1)(C)
|
|
Notice of Guaranteed Delivery.*
|
|
|
(a)(1)(D)
|
|
Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
|
|
|
(a)(1)(E)
|
|
Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*
|
|
|
(a)(1)(F)
|
|
Summary Advertisement as published in
The New York Times
on January 19, 2017.*
|
|
|
(a)(1)(G)
|
|
Press Release, dated January 9, 2017 (incorporated by reference to Exhibit 99.1 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange
Commission on January 9, 2017).*
|
|
|
(a)(1)(H)
|
|
Press Release, dated January 9, 2017, as filed with the Tokyo Stock Exchange (incorporated by reference to Exhibit 99.2 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited
with the U.S. Securities and Exchange Commission on January 9, 2017).*
|
|
|
(a)(1)(I)
|
|
Tweet from January 9, 2017, by Takeda Oncology (@TakedaOncology) (incorporated by reference to Exhibit 99.3 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited with the
U.S. Securities and Exchange Commission on January 9, 2017).*
|
|
|
(a)(1)(J)
|
|
LinkedIn posting from January 9, 2017, by Takeda Oncology (incorporated by reference to Exhibit 99.4 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited with the U.S.
Securities and Exchange Commission on January 9, 2017).*
|
|
|
(a)(1)(K)
|
|
Facebook posting from January 9, 2017, by Takeda Oncology (incorporated by reference to Exhibit 99.5 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited with the U.S.
Securities and Exchange Commission on January 9, 2017).*
|
|
|
(a)(1)(L)
|
|
Letter, dated January 9, 2017, from Christophe Weber to employees of ARIAD Pharmaceuticals, Inc. (incorporated by reference to Exhibit 99.6 to the Schedule
TO-C
filed by Takeda
Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 9, 2017).*
|
|
|
(a)(1)(M)
|
|
Excerpts from presentation at J.P. Morgan Healthcare Conference 2017, dated January 9, 2017 (incorporated by reference to Exhibit 99.1 to the Schedule
TO-C
filed by Takeda Pharmaceutical
Company Limited with the U.S. Securities and Exchange Commission on January 10, 2017).*
|
|
|
(a)(1)(N)
|
|
Presentation Accompanying Conference Call, dated January 9, 2017 (incorporated by reference to Exhibit 99.2 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited with the
U.S. Securities and Exchange Commission on January 10, 2017).*
|
|
|
(a)(1)(O)
|
|
Excerpts from transcript of presentation at J.P. Morgan Healthcare Conference 2017, dated January 9, 2017, link available on Takedas external website (incorporated by reference to Exhibit 99.1 to the Schedule
TO-C
filed by Takeda Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 11, 2017).*
|
|
|
(a)(1)(P)
|
|
Transcript of Conference Call, dated January 9, 2017, available on Takedas external website (incorporated by reference to Exhibit 99.2 to the Schedule
TO-C
filed by Takeda
Pharmaceutical Company Limited with the U.S. Securities and Exchange Commission on January 11, 2017).*
|
|
|
|
|
|
(a)(1)(Q)
|
|
Press Release, dated January 19, 2017.*
|
|
|
(b)
|
|
None.
|
|
|
(d)(1)
|
|
Agreement and Plan of Merger, dated as of January 8, 2017 between ARIAD Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and Kiku Merger Co., Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form
8-K filed by ARIAD Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on January 10, 2017).*
|
|
|
(d)(2)
|
|
Confidentiality Agreement, dated as of December 18, 2016, between ARIAD Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.*
|
|
|
(d)(3)
|
|
Exclusivity Agreement, dated as of December 26, 2016, among ARIAD Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.*
|
|
|
(d)(4)
|
|
Form of Tender and Support Agreement (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K filed by ARIAD Pharmaceuticals, Inc. with the U.S. Securities and Exchange Commission on January 10, 2017).*
|
|
|
(g)
|
|
None.
|
|
|
(h)
|
|
None.
|
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Oct 2023 to Oct 2024